Aditxt, Inc., a health innovation company, announced on October 29, 2024, the appointment of Sylvia Hermina to its Board of Directors, effective October 23, 2024. Hermina, with over two decades of experience in corporate governance, mergers and acquisitions, and shareholder relations, is expected to bring valuable insights and strategies to Aditxt. Her appointment is part of the company's efforts to incorporate diverse perspectives at the decision-making level, particularly as it expands into women's health. Hermina's background includes senior roles at Kingsdale Advisors and Laurel Hill Advisory Group, and she is a member of the Society of Corporate Governance & the National Investor Relations Institute. Aditxt is currently engaged in immune and precision health programs and plans to introduce new programs in public health and women's health, pending transactions with Appili Therapeutics, Inc. and Evofem Biosciences, Inc. The completion of these transactions is contingent upon certain conditions, including shareholder approvals and sufficient capital raising by Aditxt.

Aditxt, Inc., a health innovation company, announced on October 29, 2024, the appointment of Sylvia Hermina to its Board of Directors, effective October 23, 2024. Hermina, with over two decades of experience in corporate governance, mergers and acquisitions, and shareholder relations, is expected to bring valuable insights and strategies to Aditxt. Her appointment is part of the company's efforts to incorporate diverse perspectives at the decision-making level, particularly as it expands into women's health. Hermina's background includes senior roles at Kingsdale Advisors and Laurel Hill Advisory Group, and she is a member of the Society of Corporate Governance & the National Investor Relations Institute. Aditxt is currently engaged in immune and precision health programs and plans to introduce new programs in public health and women's health, pending transactions with Appili Therapeutics, Inc. and Evofem Biosciences, Inc. The completion of these transactions is contingent upon certain conditions, including shareholder approvals and sufficient capital raising by Aditxt.